Placenta will be collected and from these, mitochondrial will be harvested. Mitochondria will be used in mitochondrial augmentation therapy.
Healthy pregnant females between the age of 18-45, judged to be medically eligible by the Investigator and the Sponsor's Medical Monitor.
Planned elective C-section at weeks 36-41 of pregnancy.
Uncomplicated pregnancy as determined by the Investigator.
Available Medical History of the donor (diagnosis, diseases, medication etc…)
Donor is positive for a communicable disease, such as: HBV, HCV, HIV 1&2, WNV, HTLV 1&2, Treponema pallidum, CMV, Chagas, Chlamydia Trachomatis, Neisseria Gonorrhea, or any other tests required by the medical facility, IMoH, FDA, EMA or the Sponsor.
Donor is at risk for a communicable disease as assessed by medical history, medical records, physical exam, and the Donor Screening Questionnaire.
Donor is at risk for COVID-19 as assessed by medical history, medical records, physical exam, and the COVID-19 Screening Questionnaire.
Donor smokes more than one pack of cigarettes a day or drinks more than one alcoholic beverage a day.
Pregnant females giving term birth by C-section
Case-only
Prospective
Not listed
Placenta donated
The purpose of this study is to collect placenta for the production of mitochondria. Therefore, only general measurements are taken such as placenta weight and health of mother during pregnancy. No further intervention or interaction with the mother will occur, and she does not receive any drug product or treatment prior to or after placenta donation.
Click on the lead sponsor to view all of their trials.
